BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
ZacksBioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?